Co-ingestion of aspirin and acetaminophen promoting fulminant liver failure: A critical review of Reye syndrome in the current perspective at the dawn of the 21st century.
Deepak DinakaranConsolato Maria SergiPublished in: Clinical and experimental pharmacology & physiology (2017)
In the paediatric population, there is some evidence of possible interaction, synergism, and co-toxicity of aspirin and acetaminophen. The toxicity of salicylates such as aspirin in this population is well known and documented, specifically in the form of Reye syndrome. The possible toxic synergism with aspirin and acetaminophen, however, is not previously described; though case reports suggest such co-toxicities with low levels of aspirin and other compounds can exist. In vitro studies into mechanistic processes of salicylate toxicity propose that there is a bi-directional link and potentiation with glutathione (GSH) depletion and salicylate toxicity. Data may suggest a plausible explanation for salicylate and acetaminophen toxic synergism. Further studies investigating this potential toxic synergism are warranted. Given the lack of awareness in the clinical community about potential toxic synergism between these relatively common medications, caution is advised in the co-administration of these drugs, particularly in communities using natural or alternative therapy.
Keyphrases
- low dose
- antiplatelet therapy
- cardiovascular events
- liver failure
- liver injury
- oxidative stress
- case report
- anti inflammatory drugs
- drug induced
- hepatitis b virus
- acute coronary syndrome
- percutaneous coronary intervention
- intensive care unit
- emergency department
- mental health
- oxide nanoparticles
- type diabetes
- big data
- mesenchymal stem cells
- deep learning